Kenneth Chng

Kenneth Chng has a background in microbiology and immunology. At Lynx Biosciences, Kenneth performed various roles as the third employee in a biotech startup focused on utilizing a diagnostic platform for predicting drug response in blood cancer patients. Kenneth later moved on to Plexium where Kenneth currently holds a senior scientist position in screening, assay, and technology development. Prior to their industry experience, Kenneth worked as an associate research scientist at the University of Wisconsin, focusing on investigating the role of HAPLN1 in bortezomib-resistant NF-κB pathway activation.